Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  De Oliveira, Tiago ^a,b   Abiatari, Ivane ^a   Raulefs, Susanne ^a   Sauliunaite, Danguole ^a   Erkan, Mert ^a   Kong, Bo ^a   Friess, Helmut ^a   Michalski, Christoph W ^a   Kleeff, Jörg ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b International Max Planck Research School   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN CDC42; SYNDECAN 2;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PANCREAS ADENOCARCINOMA; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA; CELL MOTION; GENETICS; IMMUNOBLOTTING; METABOLISM; MIDDLE AGED; PANCREAS; PANCREAS TUMOR; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SYNDECAN-2;

EID: 84859192829     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-19     Document Type: Article

References (46)

1. Jemal A, et al. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Dai H, et al. Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. Hum Pathol 2007, 38(2):299-307. 10.1016/j.humpath.2006.08.002, 17097719.
3. Kleeff J, et al. Pancreatic cancer microenvironment. Int J Cancer 2007, 121(4):699-705. 10.1002/ijc.22871, 17534898.
4. Singh A, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15(6):489-500. 10.1016/j.ccr.2009.03.022, 2743093, 19477428.
5. Campbell PM, et al. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007, 67(5):2098-2106. 10.1158/0008-5472.CAN-06-3752, 17332339.
6. Esposito I, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008, 15(6):1651-1660. 10.1245/s10434-008-9839-8, 18351300.
7. Gotte M. Syndecans in inflammation. FASEB J 2003, 17(6):575-591. 10.1096/fj.02-0739rev, 12665470.
8. Munesue S, et al. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 2007, 282(38):28164-28174. 10.1074/jbc.M609812200, 17623663.
9. Couchman JR. Syndecans: proteoglycan regulators of cell-surface microdomains?. Nat Rev Mol Cell Biol 2003, 4(12):926-937. 10.1038/nrm1257, 14685171.
10. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol 2006, 6(9):633-643. 10.1038/nri1918, 16917509.
11. Conejo JR, et al. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 2000, 88(1):12-20. 10.1002/1097-0215(20001001)88:1<12::AID-IJC3>3.0.CO;2-T, 10962434.
12. Abiatari I, et al. Consensus transcriptome signature of perineural invasion in pancreatic carcinoma. Mol Cancer Ther 2009, 8(6):1494-1504. 10.1158/1535-7163.MCT-08-0755, 19509238.
13. Kaur C, et al. Expression of syndecan-2 in the amoeboid microglial cells and its involvement in inflammation in the hypoxic developing brain. Glia 2009, 57(3):336-349. 10.1002/glia.20764, 18803305.
14. Granes F, et al. Ezrin links syndecan-2 to the cytoskeleton. J Cell Sci 2000, 113(Pt 7):1267-1276.
15. Landgraf P, et al. The survival-promoting peptide Y-P30 enhances binding of pleiotrophin to syndecan-2 and -3 and supports its neuritogenic activity. J Biol Chem 2008, 283(36):25036-25045. 10.1074/jbc.M800963200, 3259816, 18599487.
16. Klass CM, Couchman JR, Woods A. Control of extracellular matrix assembly by syndecan-2 proteoglycan. J Cell Sci 2000, 113(Pt 3):493-506.
17. Munesue S, et al. The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones. Biochem J 2002, 363(Pt 2):201-209. 1222468, 11931647.
18. Park H, et al. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 2002, 277(33):29730-29736. 10.1074/jbc.M202435200, 12055189.
19. Kim Y, et al. Decreased syndecan-2 expression correlates with trichostatin-A induced-morphological changes and reduced tumorigenic activity in colon carcinoma cells. Oncogene 2003, 22(6):826-830. 10.1038/sj.onc.1206068, 12584561.
20. Lee JH, et al. Syndecan-2 regulates the migratory potential of melanoma cells. J Biol Chem 2009, 284(40):27167-27175. 10.1074/jbc.M109.034678, 2785644, 19641225.
21. Jiang X, et al. Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer. Pancreatology 2009, 9(1-2):165-172. 10.1159/000178888, 19077468.
22. Michalski CW, et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 2008, 122(4):742-750. 10.1002/ijc.23114, 2225529, 17943729.
23. Abiatari I, et al. Moesin Dependent Cytoskeleton Remodeling Is Associated with an Anaplastic Phenotype of Pancreatic Cancer. J Cell Mol Med 2009, 14(5):1166-1179.
24. Michalski CW, et al. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. PLoS One 2008, 3(2):e1701. 10.1371/journal.pone.0001701, 2253501, 18301776.
25. Kayed H, et al. BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion. Mol Cancer 2007, 6:83. 10.1186/1476-4598-6-83, 2245975, 18163903.
26. Couchman JR, Chen L, Woods A. Syndecans and cell adhesion. Int Rev Cytol 2001, 207:113-150.
27. Oh ES, Woods A, Couchman JR. Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C. J Biol Chem 1997, 272(18):11805-11811. 10.1074/jbc.272.18.11805, 9115237.
28. Contreras HR, et al. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol Oncol 2010, 28(5):534-540. 10.1016/j.urolonc.2009.03.018, 19450993.
29. Orosco A, et al. Syndecan-2 affects the basal and chemotherapy-induced apoptosis in osteosarcoma. Cancer Res 2007, 67(8):3708-3715. 10.1158/0008-5472.CAN-06-4164, 17440083.
30. Choi S, et al. Syndecan-2 overexpression regulates adhesion and migration through cooperation with integrin alpha2. Biochem Biophys Res Commun 2009, 384(2):231-235. 10.1016/j.bbrc.2009.04.093, 19394307.
31. Han I, Park H, Oh ES. New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells. J Mol Histol 2004, 35(3):319-326.
32. Sun C, et al. Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines. Oncol Rep 2001, 8(1):89-92.
33. Tkachenko E, Rhodes JM, Simons M. Syndecans: new kids on the signaling block. Circ Res 2005, 96(5):488-500. 10.1161/01.RES.0000159708.71142.c8, 15774861.
34. Oh ES, Woods A, Couchman JR. Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C. J Biol Chem 1997, 272(13):8133-8136. 10.1074/jbc.272.13.8133, 9079625.
35. Dews IC, Mackenzie KR. Transmembrane domains of the syndecan family of growth factor coreceptors display a hierarchy of homotypic and heterotypic interactions. Proc Natl Acad Sci USA 2007, 104(52):20782-20787. 10.1073/pnas.0708909105, 2410079, 18093920.
36. Bhatt AS, et al. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 2005, 24(34):5333-5343. 10.1038/sj.onc.1208582, 3023961, 16007225.
37. Jones RJ, et al. Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM12C human colorectal cancer cells. Br J Cancer 2002, 87(10):1128-1135. 10.1038/sj.bjc.6600594, 2376185, 12402152.
38. Kinnunen T, et al. Cortactin-Src kinase signaling pathway is involved in N-syndecandependent neurite outgrowth. J Biol Chem 1998, 273(17):10702-10708. 10.1074/jbc.273.17.10702, 9553134.
39. Granes F, et al. Identification of a novel Ezrin-binding site in syndecan-2 cytoplasmic domain. FEBS Lett 2003, 547(1-3):212-216. 10.1016/S0014-5793(03)00712-9, 12860416.
40. Huang JW, Chen CL, Chuang NN. P120-GAP associated with syndecan-2 to function as an active switch signal for Src upon transformation with oncogenic ras. Biochem Biophys Res Commun 2005, 329(3):855-862. 10.1016/j.bbrc.2005.02.045, 15752734.
41. Huang JW, Chuang NN. Shift syndecan-2 from RACK1 to caveolin-2 upon transformation with oncogenic ras. Biochem Biophys Res Commun 2006, 350(1):227-232. 10.1016/j.bbrc.2006.09.035, 16997272.
42. Chu LY, Chen YH, Chuang NN. Dimerize RACK1 upon transformation with oncogenic ras. Biochem Biophys Res Commun 2005, 330(2):474-482. 10.1016/j.bbrc.2005.03.011, 15796907.
43. Sipos B, et al. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003, 442(5):444-452.
44. Kalthoff H, et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993, 8(2):289-298.
45. Schweizerhof M, et al. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med 2009, 15(7):802-807. 10.1038/nm.1976, 19525966.
46. Hrabar D, et al. Epithelial and stromal expression of syndecan-2 in pancreatic carcinoma. Anticancer Res 2010, 30(7):2749-2753.